- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | 555 | GlobeNewswire (Europe) | Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo... ► Artikel lesen | |
| 01.05. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | CERO THERAPEUTICS HOLDINGS, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.04. | CERO THERAPEUTICS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 14.04. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 14.04. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | 187 | GlobeNewswire (Europe) | Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 01.04. | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 30.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | 220 | GlobeNewswire (Europe) | Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.... ► Artikel lesen | |
| 11.03. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder Update | 233 | GlobeNewswire (Europe) | Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead... ► Artikel lesen | |
| 13.02. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient | 1 | GlobeNewswire (USA) | ||
| 03.02. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML | 170 | GlobeNewswire (Europe) | Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| 19.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) | 219 | GlobeNewswire (Europe) | Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 05.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.12.25 | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Trading on OTCQB Market | 217 | GlobeNewswire (Europe) | Company's Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"),... ► Artikel lesen | |
| 02.12.25 | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | +1,42 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| CYTOMX THERAPEUTICS | 3,265 | -1,09 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update | - Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CAPRICOR | 25,400 | -5,29 % | Capricor stock price target held at $63 by B.Riley on FDA progress | ||
| CORMEDIX | 6,320 | -1,28 % | CorMedix Q1 2026 Earnings Preview | ||
| MINERVA NEUROSCIENCES | 5,080 | +6,99 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates | Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened
Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug... ► Artikel lesen | |
| REPLIMUNE | 4,530 | +30,17 % | Replimune surges day after FDA Commissioner Makary resigns | ||
| VALERIO THERAPEUTICS | 0,153 | +0,13 % | Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches | Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,080 | -1,82 % | Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy | SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 22,990 | -6,39 % | Alto Neuroscience GAAP EPS of -$0.80 | ||
| OSR HOLDINGS | 0,617 | -3,97 % | OSR Holdings, Inc.: CEO Statement to Shareholders | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| QIAGEN | 28,350 | -1,56 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | +2,24 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,11 % bei einem Aktienkurs von 0,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.